CALT Key Statistics, Chart & Performance
The current stock price of CALT is 40.0001 USD. In the past month the price decreased by -1.33%. In the past year, price increased by 117.04%.
CALT Latest News, Press Relases and Analysis
CALT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.53B | ||
| MRK | MERCK & CO. INC. | 11.9 | 260.19B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.16B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.10B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About CALT
Company Profile
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. The company is headquartered in Stockholm, Stockholm and currently employs 219 full-time employees. The company went IPO on 2018-06-29. The company is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
Company Info
Calliditas Therapeutics AB
D5, Kungsbron 1,
Stockholm STOCKHOLM 11122 SE
CEO: Renee Aguiar-Lucander
Employees: 219
Phone: 4684113005.0
Calliditas Therapeutics AB / CALT FAQ
What does CALT do?
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. The company is headquartered in Stockholm, Stockholm and currently employs 219 full-time employees. The company went IPO on 2018-06-29. The company is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
What is the current price of CALT stock?
The current stock price of CALT is 40.0001 USD. The price decreased by -0.4% in the last trading session.
What is the dividend status of Calliditas Therapeutics AB?
CALT does not pay a dividend.
What is the ChartMill technical and fundamental rating of CALT stock?
CALT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for CALT stock?
Calliditas Therapeutics AB (CALT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.76).
Can you provide the growth outlook for Calliditas Therapeutics AB?
The Revenue of Calliditas Therapeutics AB (CALT) is expected to grow by 70.05% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for Calliditas Therapeutics AB?
Calliditas Therapeutics AB (CALT) currently has 219 employees.
CALT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CALT. When comparing the yearly performance of all stocks, CALT is one of the better performing stocks in the market, outperforming 95.05% of all stocks.
CALT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CALT. Both the profitability and financial health of CALT have multiple concerns.
CALT Financial Highlights
Over the last trailing twelve months CALT reported a non-GAAP Earnings per Share(EPS) of -1.76. The EPS decreased by -64.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.49% | ||
| ROE | -449.82% | ||
| Debt/Equity | 9.44 |
CALT Forecast & Estimates
13 analysts have analysed CALT and the average price target is 45.37 USD. This implies a price increase of 13.42% is expected in the next year compared to the current price of 40.0001.
For the next year, analysts expect an EPS growth of 127% and a revenue growth 70.05% for CALT